Pharma Giants' $454M Glumetza Antitrust Deal Gets Initial OK
By Hannah Albarazi (September 22, 2021, 5:04 PM EDT) -- U.S. District Judge William Alsup preliminarily approved $454 million in settlements Wednesday resolving direct buyers' allegations that Bausch Health Cos. Inc., Lupin Pharmaceuticals Inc. and Assertio Therapeutics Inc. plotted to delay the blockbuster diabetes drug Glumetza's generic version, but warned the parties not to make it difficult for class members to opt out.
Judge Alsup said he would preliminarily approve three settlements — Bausch's $300 million deal, Lupin's $150 million deal and Assertio's $3.85 million deal — to end antitrust litigation by direct buyers claiming brand-name drugmakers Bausch and Assertio paid off generics maker Lupin to stave off the launch of...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!